<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40955889</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-5772</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of the Association of Physicians of India</Title><ISOAbbreviation>J Assoc Physicians India</ISOAbbreviation></Journal><ArticleTitle>Newer Therapies for Osteoporosis: A Systematic Review.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>76</EndPage><MedlinePgn>67-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.59556/japi.73.1084</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The current management of osteoporosis has several unmet needs. Consequently, the newer and upcoming agents and targets are being expectantly looked at. We aim to appraise the evidence examining the efficacy of the newer therapies for the management of osteoporosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Scopus, Embase, and MEDLINE databases were screened from January 2013 to December 2023 to identify clinical trials that evaluated the efficacy of newer agents for the treatment of osteoporosis in men and postmenopausal women (PMO). Changes in bone mineral density (BMD) and incidences of vertebral fractures (VFs) and nonvertebral fractures (NVFs) or relative risk reduction (RRR) for VF and NVF were retrieved. The Oxford quality scoring system was applied to evaluate the methodological quality of the included clinical trials.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen randomized controlled trials (RCTs) that had enrolled 22,868 PMO and 473 male participants were included. Anabolic agents abaloparatide and romosozumab exhibited significant BMD gain and relative RRR for fractures and greater efficacy than teriparatide. Blosozumab was reported to exhibit substantial BMD gains. The efficacy of a sequential therapeutic strategy with anabolic agent followed by antiresorptive agents was superior to the reverse sequence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Newer therapies for osteoporosis exhibited significant BMD gain and fracture risk reduction in men and PMO. The newer anabolic agents demonstrated greater efficacy than any of the previously available therapeutic options.</AbstractText><CopyrightInformation>&#xa9; Journal of The Association of Physicians of India 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Parthajit</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rheumatologist, Department of Rheumatology, Asian Institute of Immunology and Rheumatology, Kolkata, West Bengal, India, Orcid: https://orcid.org/0000-0002-1788-846X, Corresponding Author.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatologist, Division of Rheumatology, CARE Pain and Arthritis Centre, Udaipur, Rajasthan, India, Orcid: https://orcid.org/0000-0002-7228-2890.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Debaditya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rheumatologist, Department of Clinical Immunology and Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India, Orcid: https://orcid.org/0000-0001-9306-545X.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravindran</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rheumatologist, Department of Rheumatology, Centre for Rheumatology, Calicut, Kerala; Adjunct Professor, Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India, Orcid: https://orcid.org/0000-0001-5842-1877.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><MedlineTA>J Assoc Physicians India</MedlineTA><NlmUniqueID>7505585</NlmUniqueID><ISSNLinking>0004-5772</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>AVK0I6HY2U</RegistryNumber><NameOfSubstance UI="C000596789">abaloparatide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3VHF2ZD92J</RegistryNumber><NameOfSubstance UI="C557282">romosozumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044162">Parathyroid Hormone-Related Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="Y">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="Y">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058866" MajorTopicYN="N">Osteoporotic Fractures</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016103" MajorTopicYN="N">Spinal Fractures</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045930" MajorTopicYN="N">Anabolic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N" AutoHM="Y">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044162" MajorTopicYN="N" AutoHM="Y">Parathyroid Hormone-Related Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>7</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40955889</ArticleId><ArticleId IdType="doi">10.59556/japi.73.1084</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>